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Bone marrow stromal cells (BMSCs, also known as bone marrow-derived mesenchymal stem cells) are fibroblastic reticular
cells, a subset of which is composed of multipotent skeletal stem cells (SSCs). SSCs/BMSCs are able to recreate a bone/marrow
organ in vivo. To determine differences between clonogenic multipotent SSCs and similarly clonogenic but non-multipotent
BMSCs, we established single colony-derived strains (SCDSs, initiated by individual Colony Forming Unit-Fibroblasts) and
determined their differentiation capacity by vivo transplantation. In this series of human SCDSs (N = 24), 20.8% formed fibrous
tissue (F), 66.7% formed bone (B), and 12.5% formed a bone/marrow organ, and thus were multipotent (M). RNA isolated from
12 SCDSs just prior to transplantation was analyzed by microarray. Although highly similar, therewas variability from one SCDS to
another, and SCDSs did not strictly segregate into the three functional groups (F, B or M) by unsupervised hierarchical clustering.
We then compared 3 F-SCDSs to 3 M-SCDSs that did segregate. Genes associated with skeletogenesis, osteoblastogeneis,
hematopoiesis, and extracellular matrix were over-represented in M-SCDSs compared with F-SCDSs. These results highlight the
heterogeneity of SSCs/BMSCs, even between functionally similar SCDSs, but also indicate that differences can be detected that
may shed light on the character of the SSC.
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Bone marrow (BM) stromal cells (BMSCs, also known as bone
marrow-derivedmesenchymal stem cells) were first identified
and characterized by Friedenstein and Owen as a rapidly
adherent, fibroblastic population of cells that contain a subset
ofmultipotent stem cells (reviewed in Owen and Friedenstein,
1988). These cells are capable of recreating the hema-
topoietic microenvironment when transplanted in vivo
(Friedenstein et al., 1974) by generating a bone/marrow
organ. These ectopic ossicles have been consistently found to
be composed of bone, hematopoiesis-supporting stroma,
marrow adipocytes of donor origin, and hematopoiesis of
recipient origin (Balakumaran et al., 2010; Dieudonne et al.,
1998; Krebsbach et al., 1997; Kuznetsov et al., 1997; Sacchetti
et al., 2007). Subsequent studies have shown that these
skeletal stem cells (SSCs, Bianco and Robey, 2004) are
self-renewing, sub-endothelial cells that line BM sinusoids
(pericytes) and send out processes that intercalate into areas
of hematopoiesis (Sacchetti et al., 2007). Consequently, SSCs
are hypothesized to be important participants in the hemato-
poietic stem cell (HSC) niche (Mendez-Ferrer et al., 2010;
Sacchetti et al., 2007).
Much work has been done on studying the biological
activities of BMSCs in vitro. While in vitro assays are valuable
tools to address specific questions, they are not well suited for
studying the biological activities of SSCs directly, due to the
fact that the latter represent only a subset of cells within the
BMSC population. Furthermore, there is no single marker or
set of markers that can efficiently separate SSCs from non-
multipotent BMSCs (Bianco et al., 2008), and even if there
were, ex vivo expansion would result again in a mixture of
stem cells andmore committed cells due to the kinetics of cell
division (reviewed in Neumuller and Knoblich, 2009). If one
assumes that stem cell division is strictly asymmetrical (one
cell remaining a stem cell, the other a more committed cell),
the stem cell subset would rapidly be diluted by transiently
amplifying cells that are not stem cells (Kuznetsov et al.,
2004). In addition, while SSCs are clearly a component of the
HSC niche, current culture conditions required for support of
human HSCs in vitro are not optimal (Lymperi et al., 2010). For
these reasons, in vivo transplantation is the gold standard by
which to characterize the differentiation capacity of a clonal
BMSC population, in particular with regard to the formation of
hematopoiesis-supportive stroma, a defining feature of SSCs
(Bianco, 2011). Furthermore, only a subset of freshly isolated
BMSCs are capable of density-independent growth [Colony
Forming Unit-Fibroblasts (CFU-Fs)], and the resulting clones
are heterogeneous in their in vitro differentiation potential
(Muraglia et al., 2000; Pittenger et al., 1999; Russell et al.,
2010 as examples), and their ability to recreate a bone/
marrow organ in vivo (Friedenstein, 1980; Gronthos et al.,
2003; Kuznetsov et al., 1997; Sacchetti et al., 2007). In these
studies, 10–20% of the single colony-derived strains (SCDSs,
initiated by individual CFU-Fs) formed a bone/marrow organ,
while the remainder formed only bone (35–45%) or fibrous
tissue (35–55%).
Currently, the molecular profile of subsets of SSCs/BMSCs
with varying differentiation potentials is largely undefined.
Larsen et al. previously established transcription profiles that
distinguish between immortalized clones with and without theability to form bone in vivo (Larsen et al., 2010). Clones that
formed bone had increased expression of extracellular matrix
genes, and those that did not form bone expressed immune
response-related genes. Here we present data from primary
unmodified SCDSs. We first established the functionality of
human SCDSs by in vivo transplantation, and then compared
the molecular signature of SCDSs that regenerated a complete
bone/marrow organ with those that formed only fibrous
tissue.Materials and methods
Generation of BM single cell suspensions
A suspension of BM nucleated cells (BMNCs) was prepared from
human trabecular bone from surgical waste of a single donor
(female, 43 years-old) according to NIH guidelines as previ-
ously described (reviewed in Robey et al., 2014). Briefly, BM
was gently scraped from bone fragments into growth medium
[α-MEM, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL
streptomycin (all from Invitrogen), and 20% lot-selected,
non-heat inactivated fetal bovine serum (HyClone)], and the
fragments were washed extensively to remove marrow. After
pelleting by centrifugation, bone marrow nucleated cells
(BMNCs) were resuspended in growth medium, and passed
through a 16 gauge needle, and subsequently through a 70 μm
cell strainer (Becton Dickinson) to remove aggregates.Generation of SCDSs and non-clonal BMSCs
SCDSs were prepared as previously described (Robey et al.,
2014). BMNCs were plated at low density (2 × 103 nucleated
cells/cm2) into 150 mm2 tissue culture dishes (Becton
Dickinson), and cultured in growth medium at 37 °C for
14 d without any media replacements. After 14 d, single
colonies with N50 cells were randomly selected and
individually isolated. Only colonies with a round morphology
and obvious separation from surrounding colonies were
chosen. The colonies were isolated by attaching a cloning
cylinder (Bel-Art Products) to the dish using sterile vacuum
grease (Baxter Healthcare Corp.). Cells were detached with
0.05% Trypsin/EDTA (Invitrogen), and transferred to 1well of a
6-well dish (Becton Dickinson) with growth medium. Once the
cells approached confluency, they were passaged consecu-
tively into one 75 cm2 flask (Becton Dickinson), and then into
two 75 cm2 flasks. Once these flasks became confluent, the
cells were detached and used for RNA isolation and in vivo
transplantation. In some cases, SCDSs generated previously
and cryopreserved from another donor, were used in exper-
iments described below. Non-clonal BMSC cultures were
established by plating BMNCs at a density of 5 × 106–
5 × 107 cells/75 cm2 tissue culture flask in growth medium
as previously described (Robey et al., 2014).RNA isolation
RNA was isolated from at least 5 × 105 cells from each SCDS or
non-clonal BMSC cultures with TRIzol (Invitrogen), and further
purified by using a combination of chloroform phase
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manufacturer's protocol.
In vivo transplantation of SCDSs
2 × 106 cells from each SCDS were suspended in growth
medium and incubated at 37 °C on a rotator with 40 mg
of sterile hydroxyapatite/tricalcium phosphate particles
(HA/TCP, Zimmer). After 90 min, the particles and cells
were collected by brief centrifugation and transplanted
subcutaneously into the flank of an immunodeficient mouse
(NIH-Lystbg-JFoxn1nuBtkxid, Charles River). After 8 wks,
the mice were euthanized and the transplants harvested
(Krebsbach et al., 1997).
Histological scoring of in vivo transplants
Each transplant was fixed in 4% paraformaldehyde for 3 d, and
decalcified in 0.25 M EDTA. Decalcification was confirmed by
X-ray (Faxitron, 30 V for 40 s using Kodak PPL film). After
decalcification, the transplants were embedded in paraffin
and sectioned (5 μm). Each transplant was sectioned such that
a section was taken every 100 μm to generate at least five
sections, in order to ensure procurement of a representative
sample through the entire thickness of each transplant.
Sections were stained with H&E and examined microscopical-
ly. Each section was given a separate semi-quantitative score
ranging from 0 to 4 for both bone and hematopoiesis formation
by two independent, trained observers (see Mankani et al.,
2004). Bone and hematopoiesis were scored independently of
each other; for example, a section with exuberant bone
formation but less abundant hematopoiesis could receive a
score of 4 for bone formation, but only 1 for hematopoiesis.
Gene expression microarray analysis
Total RNA was extracted from cells using the RNeasy Mini Kit
(Qiagen, Valencia, CA) following the manufacturer's instruc-
tions. RNA was quantified and 5 μg was processed for
microarray analysis (LMT, NCI, Frederick, MD). RNA was reverse
transcribed to form cDNA, and hybridized to Affymetrix
GeneChip Human Genome U133 Plus 2.0 arrays, composed of
more than 54,000 probe sets and 1,300,000 distinct oligonucle-
otide features that analyze the expression level of over 47,000
transcripts and variants, including 38,500 well-characterized
human genes. Three independent replicates for each of the
experimental conditions were carried out and analyzed to
control for intra-sample variation. Comparative analyses of
expressed genes that were over/under-represented by N2-fold
were carried out using theGeneSpring software. Signal intensity
values were normalized using RMA summarization and baseline
transformation to median of all samples was performed.
Entities were filtered based on their signal intensity values. A
total of 45,371 out of 54,675 entities passed the test where 1
out of 6 samples have signal intensity values between 20 and
100 percentiles. Hierarchical clustering was performed on
filtered signal intensity (N20.0), non-averaged, fold change N
2. Gene ontology analysis was done using fold change N 2, and a
p-value cutoff of 0.1, as a p-value cutoff 0.05 resulted in no
significant GO groups. A fold change analysis (N10 fold) was
performed to generate a list of top genes over/under-represented between groups. Statistical analysis was performed
using the Student's t-test (fold change ≤ 2, corrected
p-value ≤ 0.05).qRT-PCR analysis
RNA was extracted from cells that remained after genera-
tion of in vivo transplants and microarray analysis (SCDS-61,
SCDS-11, SCDS-99, SCDS-107), from SCDSs isolated from
another donor, and from non-clonal BMSCs. RNA (1.0 μg) was
used for cDNA synthesis using the iScript cDNA Synthesis Kit
(Bio-Rad, #170-8891). Quantitative RT-PCR (qPCR) was
performed using a CFX-96 Real Time System paired with a
C1000 Thermal Cycler (Bio-Rad, Hercules, CA). qPCR reactions
were set up using iQ SYBR Green Supermix (Bio-Rad #170-8882)
according to the kit's instructions. Primers were designed
using Beacon Designer 6 software (Premier Biosoft Interna-
tional, Palo Alto, CA): hSFRP2 (NM_003013) — F: AGGACAA
CGACCTTTGCATC, R: CAGGCTTCACATACCTTTGGA; hCNN1
(NM_001299.4) — F: ACTTCATGGACGGCCTCA, R: TGGGTTG
ACTCATTGATCTTCTT; RPL13a (NM_012423) — F: GGAGAA
GAGGAAAGAGAAAGC, R: GGCAACAATGGAGGAAGG; GAPDH
(NM_002046.3) — F: TGCACCACCAACTGCTTAGC, R: GGCAT
GGACTGTGGTCATGAG. qPCR results, expressed as critical
threshold (CT) values, were normalized to the levels of
RPL13a or GAPDH, generating ΔCT values; levels of relative
expression were calculated as 2−ΔCT.Results
Generation and transplantation of SCDSs
SCDSs of hBMSCs were expanded under basal conditions, and
their in vivo differentiation potential was assayed according to
the scheme represented in Fig. 1A. Of the 114 hBMSC colonies
originally selected, ~50% ceased to proliferate. Of those that
continued to proliferate, 24 were randomly selected, trans-
planted, and harvested after 8 wks. Of note, no adipocytic
differentiation was noted in any of the SCDSs. Between ~3 and
7 × 106 cells were available at the time of transplant.Histological analysis and scoring of SCDS transplants
Sections of transplants were stained with H&E, examined
histologically, and given an independent score ranging from
0 to 4 for both bone and hematopoiesis (Mankani et al.,
2004). Those clonal strains that formed only fibrous tissue
were considered to be devoid of SSCs, and were termed
fibrous (F), those that formed bone without supporting
hematopoiesis were considered to be unipotent (B), and
those that formed bone and supported formation of marrow
(stroma and adipocytes of donor origin, hematopoiesis of
recipient origin) were considered to be multipotent (M)
(Fig. 1B). Of the 24 SCDSs transplanted, 5 (20.8%) formed
fibrous tissue (F), 16 (66.7%) formed bone (B), with scores
between 1 and 3, and 3 (12.5%) weremultipotent (M) (Fig. 1C).
These results are consistent with what has been reported
previously. Notably, only M transplants were found to have
adipocytes; adipocytes were not found in F or B transplants.
Figure 1 A) Experimental design for generation of single colony-derived strains (SCDSs), assessment of functionality by in vivo
transplantation and profiling by microarray analysis. B) Types of transplant. Twenty-four SCDSs were transplanted in vivo with
hydroxyapatite/tricalcium phosphate ceramic particles as a scaffold, and then scored on a scale of 0–4 for the presence of bone and
hematopoiesis. The SCDSs were categorized as generating fibrous tissue (no bone, no support of hematopoiesis) (F), bone-forming
only (B), and as multipotent (M) based on the formation of bone and support of hematopoiesis. C) The scores of individual transplants
were categorized, and the percentages of each type (F, B or M) are indicated.
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RNA from a total of 12 SCDSs (5 F, 4 B, and 3 M) was analyzed by
microarray. All 12 SCDSs were allowed to undergo unsupervised
hierarchical clustering based on total gene expression (Fig. 2A).Based on the heat map, the SCDSs were highly similar to one
another, but there also was a fair amount of variability. In
addition, the SCDSs did not strictly segregate into the three
distinct functional groups (F, B and M). The 3 M-SCDSs clustered
tightly together, but F-SCDSs clustered into 2 different groups.
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Figure 2 Microarray analysis of 12 SCDSs with known functionality based on the results of in vivo transplantation (5 F, 4 B, and 3 M). A)
Unsupervised hierarchical clustering and the heat map generated by microarray. B) Unsupervised hierarchical clustering and heat map of 3
M-SCDSs (M-61, M-11, M-2), and the three F-SCDSs (F-99, F-017, F-109) that were used for further analysis of the patterns of gene expression.
C) Principle component analysis of the 3 M-SCDSs (red circles) and the 3 F-SCDSs (black circles). D) GO groups highly represented in M-SCDSs
compared to F-SCDSs.
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Table 1 Genes differentially expressed by M-SCDSs relative to F-SCDSs.
Gene name Symbol Fold change Direction
A. Genes involved in skeletogenesis
Mesenchyme homeobox 2 MEOX2 4.77 Up
GNAS complex locus GNAS 2.17 Up
Eyes absent homolog 1 EYA1 2.74 Up
Paired related homeobox 1 PRRX1 2.03 Up
Calponin 1, basic, smooth muscle CNN1 11.27 Down
B. Genes involved in osteoblast differentiation
Bone morphogenetic protein 2 BMP2 2.65 Up
Bone morphogenetic protein 4 BMP4 2.34 Up
Secreted frizzled-related protein 2 SFRP2 33.14 Up
Msh homeobox 2 MSX2 2.41 Up
Insulin-like growth factor 1 IGF1 6.30 Up
Meningioma 1 MN1 2.90 Up
Wnt1-inducible-signaling pathway protein 1 WISP1 2.83 Up
C. Genes involved in hematopoiesis
Bone morphogenetic protein 4 BMP4 2.34 Up
Intercellular adhesion molecule 1 (CD54) ICAM1 2.01 Up
Interleukin 8 IL8 2.86 Up
Chemokine (C-X-C motif) ligand 1 CXCL1 4.27 Up
D. Small leucine rich repeat proteoglycans
Decorin DCN 2.33 Up
Osteoglycin OGN 35.30 Up
Osteomodulin OMD 9.93 Up
Asporin ASPN 26.43 Up
302 B.J. Sworder et al.2 F-SCDSs clustered with 3 B-SCDS, while 3 others clustered
with each other, and along with M-SCDSs. One B-SCDS clustered
separately with the M-SCDSs.
Because of the heterogeneity noted, the 3 F-SCDSs that
clustered together and the 3 M-SCDSs were chosen for
further analysis, as it would allow us to determine the
differences in gene expression between two extremes of the
differentiation spectrum (multipotent vs. fibrous). Heat
maps showing all genes (Fig. 2A), and only the genes that
were at least 10-fold differentially expressed between the
M-SCDSs and F-SCDSs (Fig. 2B), revealed that there were
considerable differences between SCDSs with the same in
vivo differentiation potential (see also Supplementary
Table 1 for genes over-and under-represented at N10-fold
and N5-fold, GEO accession number: GSE647890). This is
further reflected in principle component analysis of these
SCDSs. While the M and F groups separate, those within each
group are not tightly clustered (Fig. 2C).Ingenuity pathway analysis (IPA) of higher-level
functions
IPA was used to determine which biological and molecular
functions were significantly associated with the genes that
were different between the M-SCDSs and F-SCDSs by at least
two-fold (Fig. 2D). Among the functional categories identi-
fied were those associated with Skeletal and MuscularSystem Development and Function, Connective Tissue
Development and Function, (both pointing to the inherent
osteogenic nature of M-SCDSs), Hematological System
Development and Function, and Hematopoiesis, again
highlighting the participation of M-SCDSs in the HSC niche.Differential gene expression
Examination of genes in the IPA categories that were
significantly over-represented in M-SCDSs by N2-fold re-
vealed genes involved in skeletogenesis (Table 1A —MEOX2,
GNAS, EYA1, PRRX1) and osteoblast differentiation
(Table 1B — BMP2, BMP4, SFRP2, MSX2, IGF1, MN1,
WISP1). Interestingly, WISP3, a close relative of WISP1 was
highly under-represented (Fig. 2B). Hematopoiesis-related
genes were also over-expressed (Table 1C — BMP2, ICAM1,
IL8, CXCL1), including CXCR7 (Fig. 2B), which binds to
CXCL11 and CXCL12, although its role in hematopoiesis is
not yet known. In addition, 4 members of the small
leucine-rich repeat proteoglycan family (SLRP) were
over-represented (Table 1D — DCN, OGN, OMD, ASPN).
Based on our analyses, SFRP2 was the most significantly
over-represented gene, while CNN1 was the most signifi-
cantly under-represented (Table 1A). More information
concerning the role of these genes in skeletogenesis,
osteogenesis, hematopoiesis and extracellular matrix func-
tion can be found in the Supplementary Information.
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Figure 3 Evaluation of SFRP2 and CNN1 expression in M-SCDSs, F-SCDSs and non-clonal BMSCs by qRT-PCR. A) RNA was extracted
from cells remaining after in vivo transplantation and microarray analysis (M-SCDS-61, M-SCDS-11, F-SCDS-99 and F-SCDS-107
indicated by asterisks); no more cells were available for any of the other SCDS strains shown in Fig. 2A). SFRP2 (highly
over-represented, Fig. 2B), was variably expressed in the two remaining M-SCDSs, coinciding with what was found in the heat map
(Fig. 2B). On the other hand, expression of CNN1 (highly under-represented, Fig. 2B), was under-expressed in both M-SCDSs and highly
expressed in both F-SCDSs, consistent with what was found in the heat map (Fig. 2B). B) The ability of SFRP2 and CNN1 to distinguish
between M-SCDSs from another donor compared to non-clonal BMSCs was examined. As with the original M-SCDSs (Fig. 3A), SFRP2 was
highly variable in the series of M-SCDSs from another donor, although several M-SCDSs expressed high levels. CNN1 was clearly
under-expressed in M-SCDSs compared with non-clonal BMSCs.
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qRT-PCR
RNA was extracted from all cells that were remaining
(M-SCDS-61, M-SCDS-11, F-SCDS-99, F-SCDS-107, Fig. 3A), and
analyzed for expression of SFRP2 and CNN1, which were highly
over-represented and under-represented in M-SCDSs, respec-
tively. As shown in Fig. 3A, the expression of SFRP2was variablebetween the two M-SCDSs, with one having much higher
expression than the other, reflective of what was observed on
the heat map. On the other hand, CNN1 was more consist, with
a greatly reduced level of expression in M-SCDSs vs. F-SCDSs.
We next sought to determine whether the markers
identified in the current series of SCDSs would be detected
in the same pattern in SCDSs from a different donor. A
number of M-SCDSs from another donor had been previously
304 B.J. Sworder et al.cryopreserved; however, no F-SCDSs grown under the same
conditions were available. For that reason, we compared
the levels of SFRP2 and CNN1 expression in the M-SCDSs from
the second donor to three different non-clonal populations
of BMSCs, which are a mixture of cells at various stages of
commitment. While there was a trend for higher expression
of SFRP2 in M-SCDSs (4/19 had much higher, and 4/19 had
slightly higher expression), the difference compared with
non-clonal BMSCs was not statistically different (Fig. 3B).
This variability is similar to what was observed in the
original series of M-SCDSs (Fig. 3A). Expression of CNN1 by
the M-SCDSs was significantly lower than in non-clonal
BMSCs (Fig. 3B).Discussion
Here we establish a molecular signature for unmodified
SCDSs that were initiated by individual multipotent SSCs in
comparison with SCDSs that were initiated by cells that
were not multipotent, based upon their differentiation
capacity as determined by in vivo transplantation. Of note,
all of our SCDSs were established by clonogenic cells
(CFU-Fs), but only ~1 out of 5 was in fact multipotent, as
has been reported previously by us, and others
(Friedenstein, 1980; Gronthos et al., 2003; Kuznetsov et
al., 1997; Sacchetti et al., 2007). This reinforces the notion
that cultures of BMSCs should not be referred to as “stem
cell” cultures (as is often the case), but as cultures in which
of a subset composed of stem cells exist. Not even all CFU-Fs
are stem cells, although their enumeration provides an
approximation of the number of stem cells within a freshly
isolated single cell suspension of BM (Bianco et al., 2008).
The results show that the molecular profiles of SDSCs
were very similar to one another, but no two were alike,
supporting the view that BM stromal CFU-Fs are heteroge-
neous. It has long been noted that upon plating of cells at
clonal densities, there are differences in the size and
growth habit (monolayer or multilayering) of colonies.
Previous studies (e.g., Satomura et al., 1998) showed a
positive correlation between rate of proliferation and
multipotency of murine SCDS based on in vivo transplanta-
tion. In our current series, M-SCDSs appeared to proliferate
slightly faster than F-SCDSs based on the number of days it
took to reach the final harvest and the total number of cells
generated, but this was not statistically significant (data
not shown). Furthermore, colonies are composed of cells of
different shapes and sizes, ranging from extended fibro-
blastic cells to large flat cells (Digirolamo et al., 1999; Owen
and Friedenstein, 1988; Satomura et al., 1998). However,
the morphological nature of the colony was not predictive
of the outcome of in vivo transplantation assays (Satomura
et al., 1998). When colonies are allowed to spontaneously
differentiate upon prolonged culture, varying percentages
of osteogenic, adipogenic or non-differentiated colonies
arise (Owen and Friedenstein, 1988). This may be indicative
of commitment of a particular CFU-F to one of the stromal cell
phenotypes, as a reflection of the influences exerted on that
CFU-F during embryonic growth, and post-natal development
and homeostasis. With passage, the size and shape of the cells
become more uniform; however, heterogeneity still persists,
based on the fact that not all cells retain the ability to formcolonies upon re-plating at clonal density (Friedenstein,
1976). This is most likely due to the kinetics of SSC self-
renewal that are not yet well understood in mammalian
systems (Neumuller and Knoblich, 2009). Furthermore, the
rate of proliferation of cells within an established colony (as
would be harvested at 14 d) is not synchronized, with cells in
the periphery migrating and proliferating at a faster rate than
those that are more central (Friedenstein, 1990). These
differences result in cells within the colony being in different
phases of the cell cycle, which can impact on gene expression.
For example, alkaline phosphatase is shed from the cell during
the G2 + M phase, and is slowly regained during G1 and S
phases (Fedarko et al., 1990).
Secondly, our study showed that SCDSs did not strictly
segregate transcriptionally based on their differentiation
potential as determined by in vivo transplantation. The
basis for this is not clear, but may relate to a lack of
knowledge concerning the stages of maturation of SSCs
(pericytes) to more mature phenotypes (osteoblasts, adi-
pocytes, stromal cells). Stages of osteogenic differentiation
have been marked by use of mouse reporter lines that
suggest that Runx2 is expressed in SSCs/BMSCs, and
committed osteoprogenitors (Yoshida et al., 2002), Osterix
is expressed in immature osteogenic cells (Maes et al.,
2010), the Col1a1 2.3 kb promoter is active in more mature
osteoblastic cells (Pavlin et al., 1992), and that Osteocalcin
is expressed in very mature osteoblasts and osteocytes
(Zhang et al., 2002). However, such staging for SSC/BMSC
differentiation is not yet clear. Based on the hierarchical
clustering (Fig. 2A), it can be speculated that a cell that
initiated a B-SCDS that clustered with M-SCDSs represented
a cell that was in transition from being multipotent to a
committed osteogenic cell. Likewise, the individual cells
that initiated the F-SCDSs that clustered with other B-SCDSs
may have recently transitioned to a fibroblastic phenotype
from an osteogenic phenotype. The fact that the F-SCDSs
clustered into 2 distinct groups (one with B-SCDSs, the other
with M-SCDS) suggests that while all of the F-SCDSs could not
make bone in vivo, there may be at least two subsets of
fibroblastic BMSCs. A plausible explanation for the fact that
3 F-SCDSs clustered with M-SCDSs may relate to the fact that
committed osteogenic cells (B-SCDSs) have a quite different
repertoire of expressed genes compared to those that do
not exert an overt phenotype (M-SCDSs and F-SCDSs).
Clearly, further investigation will be needed to establish
the hierarchy of SSCs/BMSCs.
Despite the high degree of similarity between SCDSs and
the lack of strict segregation by function, we did identify
genes that were highly over-represented by comparing 3
M-SCDSs and 3 F-SCDSs (see Supplementary Information for
the role of these differentially expressed genes in
skeletogenesis, osteogenesis, hematopoiesis and extracel-
lular matrix). While there are numerous reports on the
molecular signature of “mesenchymal stem cells,” most of
these studies have focused on comparing profiles of “MSCs”
from different tissues (e.g., Al-Nbaheen et al., 2013), or
BMSCs after initiating differentiation (e.g., Delorme et al.,
2009). One study (Papadimitropoulos et al., 2014) in which
3D culture conditions appeared to maintain stemness better
that 2D conditions reported over-representation of IL8 and
DNER, and under-representation of SYNPO2, NTN4 and
LIMCH1 which were over- and under-represented by
305Molecular profile of clonal strains SSCs/BMSCs with different potenciesN2-fold respectively (data not shown) in our M-SCDSs (with
the exception of SYNPO2, which was N10-fold down
regulated, see Fig. 2). Few studies have evaluated SCDSs
for both their in vivo differentiation potential and their
molecular signature. Larsen et al. (2010) reported that their
immortalized bone-forming clone highly expressed extra-
cellular matrix genes, including DCN, IL-8 and IFI27, all of
which were expressed N2-fold higher in our M-SCDSs
(Supplementary Table 1, and data not shown), but the
status of hematopoiesis in transplants generated by this
immortalized clone was not reported. In another study,
clones isolated from different tissues, including BM, and
profiled based on rate of proliferation and differentiation,
identified TWIST1 as highly over-represented (Menicanin et
al., 2010), as it was in our M-SCDSs (N2-fold, data not
shown).
The strengths of our studies are that we were able to
detect differences in the molecular profiles of SCDSs
derived from a single donor that were initiated by
multipotent SSCs vs. BMSCs that were not. However, it is
known that the growth rate, expression of markers and
differentiation capacity are variable from donor to donor
(Phinney et al., 1999). To address this issue, we used a
series of M-SCDSs from another donor, and found that
SFRP2, while highly expressed in some M-SCDSs, was not as
robust in identifying M-SCDSs as decreased expression of
CNN1. These data highlight the need to analyze a large
series of SCDSs from more donors to identify reliable and
predictive markers. Perhaps the more significant issue
relates to the need to expand the cells ex vivo, which may
exert proliferative stress that leads to shortened telomeres,
DNA damage and changes in differentiation capacity, to
obtain sufficient numbers of cells for establishment of their
functionality by the in vivo transplantation assay and
concomitant molecular profiling. As noted above, hetero-
geneity exists within colonies, thereby masking what may
be profound differences between SSCs and cells that
become more committed as the colony is established, and
propagated. Analyzing freshly isolated single cells without
ex vivo expansion, as recently performed on hematopoietic
cells (Guo et al., 2013), would undoubtedly eliminate this
issue. Nonetheless, our results begin to better describe the
heterogeneous nature of SSCs/BMSCs that has been postu-
lated, but not clearly defined at the molecular level. Future
studies will attempt to adapt a single cell strategy, although
it will not be possible to study what a given cell would do
upon in vivo transplantation. The genes identified in our
current study may help guide identification of a single cell
profile representative of an SSC in this type of approach.
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